EMA Authorised: Ecansya (previously Capecitabine Krka) (capecitabine) — Krka, d.d., Novo mesto

View source ↗

Summary

The EMA authorised Ecansya, a capecitabine product by Krka, as a new generic cancer treatment option for breast, colon, colorectal, and gastric cancers.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Colon Cancer
• Colorectal Cancer
• Gastric Cancer

Drugs mentioned

• Ecansya (capecitabine)

Snippet

Status: Authorised. Therapeutic area: Colonic Neoplasms;Breast Neoplasms;Colorectal Neoplasms;Stomach Neoplasms. MAH: Krka, d.d., Novo mesto. Decision date: 04/04/2025